



07 May 2024

ASX ANNOUNCEMENT (ASX:CBL)

Japan Partnership

Control Bionics Ltd (ASX: CBL) is pleased to announce the signing of a Memorandum of Understanding ('MOU') with Toho Lamac Co Ltd in Japan.

This MOU is the first agreement signed as Control Bionics seeks to commercialise the NeuroStrip. Control Bionics and Toho Lamac have agreed to a cooperative relationship to develop the Japanese market for the NeuroStrip.

The NeuroStrip is a wearable, miniaturised electromyography ('EMG') device that provides Control Bionics with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.

Toho Lamac (listed on the Tokyo Stock Exchange) has recently launched its new healthcare business and this division will work with Control Bionics to launch the NeuroStrip into Japan.

Shoji Kasai, Toho Lamac's CEO said 'We are excited to be working with Control Bionics to bring their world class technology to Japan. We look forward to establishing strong demand for the NeuroStrip in the Japanese market'.

Jeremy Steele, Control Bionics' CEO said 'We are delighted to be working with Toho Lamac to commercialise the NeuroStrip in Japan. The advancement of our core technology provides Control Bionics the opportunity to establish numerous partnership relationships across multiple markets such as this agreement with Toho Lamac.'

Further Mr Steele commented 'We will be working closely with the Toho Lamac team through 2024 to develop our go-to market strategies for the Japanese market'.

This announcement was authorised by CBL CEO, Jeremy Steele.

About Toho Lamac:

Established in 1958, Toho Lamac is listed on the Tokyo Stock Exchange (TSE Code: 7422). With a rich history in serving the Japanese market, the business recently diversified its operations from import and wholesale to move into the Japanese healthcare market. Toho Lamac has extensive experience in working with international companies in supporting the growth initiatives in Japan.

About Control Bionics:

Control Bionics is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses such as Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS). Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle

Control Bionics Limited

Registered Office: Level 5, Suite 5.01, 697 Burke Road, Camberwell, Victoria, 3124, Australia

T: +61 3 9897 3576 W: www.controlbionics.com

ABN: 45 115 465 462

and is captured as EMG (Electromyography) output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics is the only such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

Control Bionics recently extended its offering to mobility with the launch of DROVE – the autonomous wheelchair module. DROVE allows powered users the independence to operate their wheelchairs in their own homes for the first time.

Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip®. This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.

Control Bionics operates in North America, Australia, Singapore and Japan.

Investors and Media

Jeremy Steele – CEO and Managing Director
jsteele@controlbionics.com

Brett Crowley - Company Secretary
brettcrowley@controlbionics.com

For further information visit the website: <https://www.controlbionics.com/>

[For Toho Lamac:](#)

CEO: Shoji Kasai
Address:
3-42-6, Yushima, Bunkyo-ku, Tokyo 113-8513, Japan
TSE Security Code: 7422